[{"id":"ae1e8c24-b294-4351-8115-ef1d4ef0a78a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04018872","created_at":"2021-11-04T14:52:58.385Z","updated_at":"2024-07-02T16:36:21.182Z","phase":"Phase 2","brief_title":"Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer","source_id_and_acronym":"NCT04018872","lead_sponsor":"Dallas VA Medical Center","biomarkers":" KDR • GLI1 • GLI3 • GLI2 • SHH","pipe":" | ","alterations":" GLI3 expression","tags":["KDR • GLI1 • GLI3 • GLI2 • SHH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/24/2026","primary_completion_date":" 06/24/2026","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2021-11-04"}]